International – Moderna’s booster vaccine for South African variant demonstrates promising early results

Moderna has revealed preclinical data evaluating its South African variant-specific vaccine candidates, with early evidence that the booster jabs may be effective against ‘variants of concern’.

Preclinical data for Moderna’s variant-specific jabs has been submitted to the pre-print server bioRxiv and will also be submitted for peer-review publication, the company said in a statement yesterday.

This includes data on two candidates – mRNA-1273.351, which targets the B.1.351 variant first identified in South Africa and mRNA-1273.211, a multivalent booster candidate that combines Moderna’s authorised vaccine against ancestral strain and mRNA-1273.351 in a single vaccine.

According to the preclinical evidence, both booster vaccine candidates increase neutralising titers against SARS-CoV-2 variants of concern in mice…